Press releases

26 May, 2015

Regulatory

Sale of shares off the market following share exchange program

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that one of its insider registered persons has executed a limited share sale following completed share swaps from Maas ...

25 May, 2015

Regulatory

Topline result of Phase III study of CicloMulsion® in acute myocardial infarction expected this quarter

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, expects to announce the topline result of the phase III CIRCUS study of CicloMulsion® in patients with a specific type of heart ...

20 May, 2015

Regulatory

NeuroVive: Interim report 1 Jan. 2015 till 31 Mar. 2015

Capital raising characterizes NeuroVive ́s first quarter

18 May, 2015

Regulatory

NeuroVive announces prospectus regarding admission to trading of new shares

The prospectus regarding the admission to trading of newly issued shares in NeuroVive Pharmaceutical AB (publ) is now available on the company's website www.neurovive.se and in the company's offices, ...

8 May, 2015

Regulatory

NeuroVive completes share issue raising SEK 70 million for the preparation of CicloMulsion®’s clinical trial in the US and commercialization in Europe

NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company", OMX:NVP) today announces that the Company has completed the directed share issue announced on May 7, 2015, whereby 1,647,059 new share ...

7 May, 2015

Regulatory

NeuroVive announces the intention to raise additional capital through a private placement

NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company", OMX:NVP) today announces that the Company intends to raise new equity through a private placement directed towards qualified instituti ...

7 May, 2015

Regulatory

Published data indicates protective effect of cyclosporine in patients with stroke

The results of a clinical phase II study indicating that cyclosporine counteracts brain injury in a subset of stroke patients undergoing thrombolysis has been published in an article co-authored by on ...

27 April, 2015

Regulatory

First patient enrolled in clinical phase II study for kidney protection during heart surgery

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that the first patient has been enrolled in a clinical phase II study for acute kidney injury using the company's prod ...

21 April, 2015

Regulatory

Clinical Phase II study with NeuroSTAT® for traumatic brain injury passes safety evaluation

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that the independent safety committee has endorsed moving on to the next dose level without any safety issues, followi ...

20 April, 2015

Regulatory

NeuroVive establishes subsidiary in Lyon and extends collaboration with HCL

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has established a subsidiary in Lyon, France. The establishment is part of a process of extending its ongoing collaboration with ...

17 April, 2015

Regulatory

Development of NVP014 for the treatment of stroke enters new phase in collaboration with Isomerase Therapeutics

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's development project NVP014 for the treatment of ischemic stroke is entering a new phase in coll ...

25 February, 2015

Regulatory

Notice of Annual General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 4 p.m. on Monday, 30 March 2015 at Medicon Vil ...